Patent Application
20100015147
Morphine and many other opioid agonists have analgesic effects that are mediated by their activation of inhibitory opioid receptors on nociceptive (pain-mediating) neurons (9). Accordingly, these opioids are administered to relieve severe pain. Morphine and many other opioid agonists, however, also have been shown to activate excitatory opioid receptors on nociceptive neurons, thereby attenuating the analgesic potency of the opioid agonists, and resulting in the development of anti-analgesia, hyperexcitability, hyperalgesia, physical dependence, psychological dependence, tolerance, and other adverse (excitatory) effects (9, 10, 12, 14, 15, 48, 51, 52). Consequently, a long-standing need has existed to develop a method which will both enhance the analgesic (inhibitory) effects of these bimodally-acting opioid agonists and block or prevent adverse (excitatory) effects associated with their administration. The present invention satisfies this need.
Previous patents have disclosed that the analgesic potency of bimodally-acting opioid agonists can be enhanced, and the tolerance/dependence liability reduced, by co-administering the bimodally-acting opioid agonists with ultralow doses of selective excitatory opioid receptor antagonists (e.g., U.S. Pat. Nos. 5,472,943; 5,512,578; 5,580,876; and 5,767,125). Excitatory opioid receptor antagonists are compounds that bind to and inactivate excitatory opioid receptors, but not inhibitory opioid receptors, on neurons in nociceptive (pain) pathways. Selective excitatory opioid receptor antagonists attenuate excitatory, but not inhibitory, opioid receptor functions in nociceptive pathways of the peripheral and central nervous systems. As a result, symptoms associated with activation of excitatory opioid receptors (e.g., anti-analgesia, hyperalgesia, hyperexcitability, physical dependence, and tolerance effects) are blocked, while the analgesic effects of the bimodally-acting opioid agonists, which are mediated by the inhibitory opioid receptors, are unmasked and thereby enhanced (10, 11, 12, 52).
Previous patents have further disclosed that ultralow doses of naltrexone, alone or in combination with low-dose methadone (e.g., U.S. Pat. No. 5,512,578), and ultralow doses of other excitatory opioid receptor antagonists alone (e.g., U.S. Pat. Nos. 5,580,876 and 5,767,125), can provide effective, long-term maintenance treatment for opioid addiction after acute detoxification, and can prevent relapse to drug abuse. Furthermore, preclinical studies have suggested that ultralow doses of selective excitatory opioid receptor antagonists can be administered alone to chronic pain patients to enhance the analgesic potency and reduce the tolerance/dependence liability of endogenous opioid peptides, such as enkephalins, dynorphins, and endorphins, which are elevated in chronic pain patients (10).
GM1 is a monosialoganglioside that is abundantly distributed on the external surface of neuronal cell membranes (23, 24, 25, 37, 62). GM1-ganglioside plays a role in regulating excitatory opioid receptors in nociceptive neurons, probably by binding to an allosteric regulatory site on opioid receptors (11, 50, 53). Previous studies (67, 68) and earlier patents (e.g., U.S. Pat. Nos. 5,321,012; 5,502,058; 5,556,838; and 5,654,281) have suggested that the analgesic potency of opioid agonists is enhanced, and the tolerance/dependence liability of endogenous opioid peptides is reduced, when opioids are co-administered with high doses of exogenous GM1-ganglioside. More recent evidence has demonstrated that intraperitoneal (i.p.) injection of low doses of exogenous GM1-ganglioside (0.1 mg/kg) in mice rapidly attenuates morphine's analgesic effects (13).
Cholera toxin consists of a non-covalently-assembled pentamer of a non-toxic B subunit (CTX-B) that is responsible for cell attachment, and a toxicogenic A subunit (CTX-A) (39). CTX-B binds selectively to GM1-ganglioside on the surface of cells, and facilitates penetration of CTX-A into the cell membrane (23, 27, 43). CTX-A selectively catalyzes the ADP-ribosylation of Gs (28, 40), resulting in inhibition of an associated GTPase (6), increased adenylate cyclase activity, and decreased efficacy of ligand-activation of Gs-coupled receptors (5, 6, 38, 41, 55).
Previous studies have shown that pretreatment of dorsal root ganglion (DRG) neurons with CTX-B selectively blocks opioid-induced prolongation of the action potential duration (APD), but not opioid-induced shortening of the APD (50), suggesting that GM1-ganglioside may regulate Gs-linked excitatory opioid receptor functions in DRG neurons. Additional studies on DRG neurons in culture have shown that chronic opioid treatment, together with administration of nanomolar concentrations of CTX-B, prevents development of tolerance to the inhibitory, APD-shortening effects of micromolar concentrations of the opioid, by preventing the development of opioid excitatory supersensitivity—a cellular manifestation related to opioid tolerance and dependence in vivo (51).
While CTX-A has been shown to block opioid excitatory effects by ADP-ribosylation of Gs (49), CTX-B blockade appears to involve interference with GM1-ganglioside regulation of opioid excitatory receptor functions. In particular, it is known that CTX-B binds with selective high affinity (KD=10−10M) to GM1-ganglioside (23, 24, 25, 37, 62). Treatment of DRG neurons with anti-GM1 antibodies has been shown selectively to block opioid-induced APD prolongation, as occurs with CTX-B (50).
The present invention is predicated on the surprising discovery that the analgesic potency of morphine—a bimodally-acting opioid agonist—is increased when morphine is co-administered in mice with CTX-B or oseltamivir—agents that inhibit specific functions of endogenous GM1-ganglioside on opioid receptors in nociceptive neurons. This discovery was unexpected, as the prior art suggested that administration of high doses of exogenous GM1-ganglioside increased the analgesic potency of opioid agonists, and attenuated morphine tolerance and dependence (67, 68). On the basis of this finding, the present invention provides a method for increasing analgesic potency of a bimodally-acting opioid agonist in a subject, by administering to the subject an analgesic or subanalgesic amount of a bimodally-acting opioid agonist, in combination with an amount of an agent that inhibits GM1-ganglioside in nociceptive neurons effective to increase the analgesic potency of the bimodally-acting opioid agonist.
Also provided by the present invention is a method for treating pain in a subject in need of treatment thereof, by administering to the subject a bimodally-acting opioid agonist in combination with an agent that inhibits GM1-ganglioside in nociceptive neurons, in amounts effective to treat the pain in the subject.
The present invention further provides a method for treating chronic pain in a subject in need of treatment thereof, by administering to the subject an agent that inhibits GM1-ganglioside in nociceptive neurons in an amount effective to treat the chronic pain in the subject.
Additionally, the present invention provides a method for treating adverse excitatory effects associated with administration of a bimodally-acting opioid agonist in a subject in need of treatment thereof, by administering to the subject an agent that inhibits GM1-ganglioside in nociceptive neurons in an amount effective to treat the adverse excitatory effects in the subject.
Finally, the present invention provides a pharmaceutical composition, comprising a pharmaceutically-acceptable carrier, an analgesic or subanalgesic amount of a bimodally-acting opioid agonist, and an amount of an agent that inhibits GM1-ganglioside in nociceptive neurons effective to increase the analgesic potency of the bimodally-acting opioid agonist in a subject to whom the composition is administered.
Additional objects of the present invention will be apparent in view of the description which follows.
The present invention provides a method for increasing analgesic potency of a bimodally-acting (excitatory/inhibitory) opioid agonist in a subject. The subject is preferably a mammal (e.g., humans, domestic animals, and commercial animals, including cows, dogs, mice, monkeys, pigs, and rats), and is most preferably a human.
As used herein, the term “opioid” refers to a natural or synthetic compound which binds to specific opioid receptors in the nervous system, and which has agonist (activation) or antagonist (inactivation) effects at these receptors. Examples of opioid compounds include, without limitation, opioid alkaloids (e.g., the agonist morphine and the antagonist naloxone) and opioid peptides (e.g., dynorphins, endorphins, and enkephalins). The term “opiate” refers to a drug derived from opium or related analogues.
As further used herein, “bimodally-acting opioid agonists” are opioid agonists that bind to, and activate, both inhibitory and excitatory opioid receptors on nociceptive neurons. “Nociceptive neurons”, or nociceptors, are neurons which respond to stimuli that are damaging or potentially damaging to the skin (e.g., intense pressure, high heat, and burning chemicals), and which thereby mediate pain. Analgesia, or relief from pain, results from activation by opioid agonists of inhibitory opioid receptors on neurons in the nociceptive (pain) pathways of the peripheral and central nervous systems. Adverse excitatory effects may result from sustained activation, by bimodally-acting opioid agonists, of excitatory opioid receptors on neurons in these nociceptive pathways. Examples of such adverse excitatory effects include, without limitation, anti-analgesia, hyperexcitability, hyperalgesia, physical dependence, psychological dependence, and tolerance, as well as constipation, nausea, respiratory depression, sedation, and vomiting.
The analgesic potency of a bimodally-acting opioid agonist may be increased by strengthening the agonist's activation of inhibitory opioid receptors in nociceptive neurons, which results in an augmented analgesic effect. Additionally, the analgesic potency of a bimodally-acting opioid agonist may be increased by reducing the agonist's activation of excitatory opioid receptors in nociceptive neurons. This attenuates anti-analgesia, hyperalgesia, hyperexcitability, physical dependence, psychological dependence, tolerance, and other adverse excitatory effects associated with administration of the bimodally-acting opioid agonist, thereby unmasking the agonist's potent opioid analgesia. Moreover, the analgesic potency of a bimodally-acting opioid agonist may be increased by strengthening the agonist's activation of inhibitory opioid receptors in nociceptive neurons while simultaneously reducing the agonist's activation of excitatory opioid receptors in nociceptive neurons.
In the method of the present invention, the analgesic potency of a bimodally-acting opioid agonist is increased in a subject by administering to the subject an analgesic or subanalgesic amount of the bimodally-acting opioid agonist, in combination with an agent that inhibits GM1-ganglioside in nociceptive neurons, in an amount effective to increase the analgesic potency of the bimodally-acting opioid agonist. It is also within the confines of the present invention that administration to a subject of an analgesic or subanalgesic amount of a bimodally-acting opioid agonist, in combination with an amount of an agent that inhibits GM1-ganglioside in nociceptive neurons, will increase the analgesic potency of a bimodally-acting opioid agonist while simultaneously attenuating adverse excitatory effects associated with administration of the bimodally-acting opioid agonist. Examples of such adverse excitatory effects include, without limitation, anti-analgesia, hyperalgesia, hyperexcitability, physical dependence, psychological dependence, and tolerance.
As disclosed herein, an agent that inhibits GM1-ganglioside in nociceptive neurons brings about a reduction in a bimodally-acting opioid agonist's activation of excitatory opioid receptors in nociceptive neurons. As a consequence, the agonist's activation of inhibitory opioid receptors is simultaneously unmasked. Thus, the reduction in activation of excitatory opioid receptors, combined with the unmasking of inhibitory opioid receptor effects, results in increased analgesic potency of a bimodally-acting opioid agonist when it is co-administered with an agent that inhibits GM1-ganglioside in nociceptive neurons. Accordingly, a much lower dose of the bimodally-acting opioid agonist may be administered to a subject than would otherwise be required in the absence of co-administration with an agent that inhibits GM1-ganglioside in nociceptive neurons. This has the added benefit of reducing or attenuating additional adverse effects associated with administration of opioid agonists (e.g., constipation, nausea, respiratory depression, sedation, and vomiting) (3, 15).
The method of the present invention comprises administering to a subject an analgesic or subanalgesic amount of a bimodally-acting opioid agonist, in combination with an amount of an agent that inhibits GM1-ganglioside in nociceptive neurons. Bimodally-acting opioid agonists suitable for use in the present invention may be identified by measuring the opioid's effect on the action potential duration (APD) of dorsal root ganglion (DRG) neurons in tissue cultures. In this regard, bimodally-acting opioid agonists are compounds which elicit a prolongation of the APD of DRG neurons at picomolar (pM) to nanomolar (nM) concentrations (e.g., excitatory effects), and a shortening of the APD of DRG neurons at μM concentrations (e.g., inhibitory effects). Suitable bimodally-acting opioid agonists include, without limitation, buprenorphine, butorphanol, codeine, dynorphins, endorphins, enkephalins, fentanyl analogues, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone; pentazocine, propoxyphene, tramadol, and other similarly-acting opioid alkaloids and opioid peptides. For the purposes of treating pain, morphine, codeine, and tramadol are preferred.
Gangliosides are a class of galactose-containing complex glycolipids (sphingolipids). They are found in highest concentration in the nervous system, particularly in gray matter, where they constitute 6% of the lipids. In gangliosides, an oligosaccharide chain containing at least one acidic sugar is attached to ceramide. The acidic sugar is N-acetylneuraminate or N-glycolylneuraminate—both of which are sialic acids. GM1 is a monosialoganglioside that is abundantly distributed on the external surface of neuronal cell membranes (23, 24, 25, 37, 62). It is formed by the addition of N-acetylgalactosamine and a galactose group. Cyclic AMP (cAMP) levels are known to stimulate neuronal levels of GM1-ganglioside, and the protein kinase A pathway is required for stimulating glycosyltransferase, the enzyme that makes GM1-ganglioside (11, 62).
As used herein, an agent that “inhibits GM1-ganglioside in nociceptive neurons” refers to an agent that reduces GM1-ganglioside activity in nociceptive neurons in a subject by disabling, disrupting, or inactivating the functions of GM1-ganglioside in nociceptive neurons in the subject, particularly the modulation or regulation of excitatory opioid receptors in nociceptive neurons, or by diminishing the levels or amount of GM1-ganglioside in nociceptive neurons in the subject. GM1-ganglioside in nociceptive neurons of a subject may be inhibited by targeting GM1-ganglioside directly. GM1-ganglioside in nociceptive neurons of a subject also may be inhibited indirectly, by targeting an enzyme or other endogenous molecule that regulates or modulates the functions or levels of GM1-ganglioside in nociceptive neurons in the subject. For example, an agent that inhibits GM1-ganglioside in nociceptive neurons may be an agent that is reactive with GM1-ganglioside. As used herein, “reactive” means the agent has affinity for, binds to, or is directed against GM1-ganglioside. Such an agent may block an allosteric GM1-binding site on excitatory opioid receptors. An agent that inhibits GM1-ganglioside in nociceptive neurons also may be an agent that regulates levels of GM1-ganglioside in nociceptive neurons in the subject.
Unless otherwise indicated, an “agent”, as used herein, shall include a protein, polypeptide, peptide, nucleic acid (including DNA or RNA), antibody, Fab fragment, F(ab′)2 fragment, molecule, compound, antibiotic, drug, and any combinations thereof. A Fab fragment is a univalent antigen-binding fragment of an antibody, which is produced by papain digestion. A F(ab′)2 fragment is a divalent antigen-binding fragment of an antibody, which is produced by pepsin digestion. Examples of agents that inhibit GM1-ganglioside in nociceptive neurons include, without limitation, CTX-B, anti-GM1-ganglioside antibody, neuraminidase inhibitors (e.g., Na2SO4, oseltamivir, and zanamivir), oligonucleotide antisense to CTX-B, agents that decrease or inhibit cAMP, and agents that decrease or inhibit glycosyltransferase—the enzyme that makes GM1-ganglioside. Preferably, the agent that inhibits GM1-ganglioside in nociceptive neurons is CTX-B or oseltamivir.
Cholera toxin consists of a noncovalently-assembled pentamer of a non-toxic B subunit (CTX-B) that is responsible for cell attachment, and a toxicogenic A subunit (CTX-A) (39). CTX-B binds with selective high affinity to GM1-ganglioside (KD=10−10M) on the cell surface, and facilitates penetration of CTX-A into the cell membrane (27, 23, 43). As used herein, “CTX-B” refers to CTXB and analogues and derivatives thereof, including, for example, a natural or synthetic functional variant of CTX-B which has CTX-B biological activity, as well as a fragment of CTX-B having CTX-B biological activity. As further used herein, the term “CTX-B biological activity” refers to the activity of a protein, peptide, or other molecule that demonstrates an ability to bind selectively to GM1-ganglioside, as described herein. CTX-B may be administered to a subject in doses ranging from 0.01-1 mg/kg per day.
CTX-B and its analogues and derivatives may be produced synthetically or recombinantly. For example, CTX-B and its analogues and derivatives may be produced and purified from a recombinant strain of Vibrio cholerae that lacks the CTX-A gene (45). CTX-B (“choleragenoid”) and recombinant CTX-B are prepared in tablet form for oral administration, and may be obtained from List Biological Labs, Inc. (Campbell, Calif.). Furthermore, recombinant CTX-B (1 mg) is used in an oral cholera vaccine (“Dukoral”) produced by SBL Vaccine (Stockholm, Sweden) (44). CTX-B in the form of a spray for nasal administration also is being developed for use as a vaccine (Maxim Pharmaceuticals, San Diego, Calif.).
In addition, CTX-B and CTX-B analogues may be isolated and purified from a culture of natural Vibrio cholerae. CTX-B protein may be isolated and purified from Vibrio cholerae using standard methods known in the art, including, without limitation, extraction (e.g., with a detergent that solubilizes the protein), affinity purification on a column, chromatography (e.g., FTLC and HPLC), immunoprecipitation (with an antibody to CTX-B), and precipitation (e.g., with isopropanol and a reagent such as Trizol). Isolation and purification of CTX-B protein may be followed by electrophoresis (e.g., on an SDS-polyacrylamide gel). CTX-B is preferably produced recombinantly, using a recombinant strain of Vibrio cholerae lacking the CTX-A gene.
Neuraminidase promotes release of influenza virus from infected cells, and facilitates virus spread within the respiratory tract. Several potent and specific inhibitors of this enzyme have been developed, and two (oseltamivir and zanamivir) have been approved for human use. Oseltamivir and zanamivir inhibit replication of both influenza A and B viruses. Early treatment with either drug reduces the severity and duration of influenza symptoms and associated complications (66).
Neuraminidase also regulates cellular levels of GM1-ganglioside. For example, administration of exogenous neuraminidase has been shown markedly to increase the concentrations of GM1-ganglioside in cell membranes of DRG cells and other neurons by enzymatic removal of neuraminic (sialic) acid from polysialylated ligands of the gangliotetraose series (11, 53, 59, 60, 64, 65, 69). This specific effect of neuraminidase on the enzymatic conversion of polysialylated gangliosides to GM1-ganglioside in neurons is quite distinct from the roles of neuraminidase in promoting release of influenza virus from infected cells and in facilitating virus spread within the respiratory tract.
In view of the foregoing, an agent that inhibits GM1-ganglioside in nociceptive neurons may be a neuraminidase inhibitor. Examples of neuraminidase inhibitors that may be useful in the present invention include, without limitation, Na2SO4, oseltamivir, zanamivir, and other similarly-acting neuraminidase inhibitors.
A recent study has demonstrated that inorganic sulfates (e.g., Na2SO4 and MgSO4) have potent inhibitory effects on mammalian neuraminidase activity in cultures of human macrophagic cells (70). Thus, these inorganic sulfates may be appropriate agents that inhibit GM1-ganglioside in nociceptive neurons, for use in the present invention. Na2SO4, for example, may be administered to a subject in need of treatment for pain in an amount on the order of 10 mg/kg per day.
Oseltamivir is an ethyl ester pro-drug that requires ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is via inhibition of influenza-virus neuraminidase, with the possibility of alteration of virus particle aggregation and release. Oseltamivir and its analogues and derivatives are available commercially. Oseltamivir is prepared in tablet form, for oral administration, under the trademark “Tamiflu”, and may be obtained from Roche Laboratories (Nutley, N.J.). Tamiflu is available as a capsule containing 75 mg of oseltamivir for oral use, in the form of oseltamivir phosphate. Tamiflu may be administered to a subject in a dose ranging from 0.1-1 mg/kg, once or twice a day.
Oseltamivir at doses that result in neuraminidase inhibition of influenza virus (66) also may be effective in decreasing GM1-ganglioside levels in nociceptive neurons. Such a decrease in levels of GM1-ganglioside would result in attenuation of the efficacy of GM1-regulated, Gs-coupled, excitatory opioid receptor-mediated hyperalgesic functions, thereby unmasking Gi/Go-coupled inhibitory opioid receptor-mediated analgesia and reducing development of tolerance and physical dependence.
In another embodiment of the present invention, the agent reactive with GM1-ganglioside is an antibody to GM1-ganglioside. The antibody of the present invention may be polyclonal or monoclonal, and may be produced by techniques well known to those skilled in the art. Polyclonal antibody, for example, may be produced by immunizing a mouse, rabbit, or rat with purified GM1-ganglioside. Monoclonal antibody then may be produced by removing the spleen from the immunized mouse, and fusing the spleen cells with myeloma cells to form a hybridoma which, when grown in culture, will produce a monoclonal antibody.
Other agents that inhibit GM1-ganglioside in nociceptive neurons may be identified using standard in vitro assays known in the art, including binding assays. For example, a candidate agent may be contacted with nociceptive neurons in cell culture, and the level of GM1-ganglioside expression in the cells may be determined using standard techniques, such as Western blot analysis. Similarly, a candidate agent may be contacted with nociceptive neurons in cell culture, and the level of GM1-ganglioside binding activity in the cells then may be determined using a CTX-B/peroxidase assay (62). Where the level of GM1-ganglioside expression or binding activity in nociceptive neurons is reduced in the presence of the candidate, it may be concluded that the candidate could be a useful agent that inhibits GM1-ganglioside in nociceptive neurons.
Once agents that inhibit GM1-ganglioside in nociceptive neurons have been identified, their suitability for use in the present invention may be ascertained by measuring their effects on the action potential duration (APD) of dorsal root ganglion (DRG) neurons in tissue cultures, as described in U.S. Pat. No. 5,472,943. In particular, agents that inhibit GM1-ganglioside in nociceptive neurons of the present invention may be compounds which selectively block the prolongation of the APD of DRG neurons that is induced by low concentrations of morphine and other bimodally-acting opioid agonists (an excitatory opioid receptor-mediated effect) in DRG neurons, but not the shortening of the APD of DRG neurons (an inhibitory opioid receptor-mediated effect) that is elicited by bimodally-acting opioid receptor agonists. Alternatively, agents that inhibit GM1-ganglioside in nociceptive neurons of the present invention may be compounds which selectively block acute thermal hyperalgesia induced in mice by low concentrations (μg/kg) of morphine and other bimodally-acting opioid agonists (an excitatory opioid receptor-mediated effect), thereby unmasking potent opioid analgesia (15).
In the method of the present invention, an analgesic or subanalgesic amount of a bimodally-acting opioid agonist is administered to a subject in combination with an agent that inhibits GM1-ganglioside in nociceptive neurons. As used herein, an “analgesic” amount is an amount of the bimodally-acting opioid agonist which causes analgesia (relief from pain) in a subject to whom the bimodally-acting opioid agonist is administered alone, and includes standard doses of the agonist which are typically administered to cause analgesia (e.g., mg doses). A “subanalgesic” amount is an amount of the bimodally-acting opioid agonist which does not cause analgesia in a subject when administered alone to the subject, but which results in analgesia when used in combination with an agent that inhibits GM1-ganglioside in nociceptive neurons.
Inhibitory opioid receptor-mediated functions, which are activated by the bimodally-acting opioid agonist, are not attenuated by administration of the agent that inhibits GM1-ganglioside in nociceptive neurons. As a result, treatment with the agent that inhibits GM1-ganglioside in nociceptive neurons enhances the analgesic potency of the bimodally-acting opioid agonist, and reduces or attenuates adverse excitatory effects associated with administration of bimodally-acting opioid agonists (e.g., anti-analgesia, hyperexcitability, hyperalgesia, physical dependence, psychological dependence, and tolerance, as well as constipation, nausea, respiratory depression, sedation, and vomiting).
When administered in combination with a bimodally-acting opioid agonist, an agent that inhibits GM1-ganglioside in nociceptive neurons may be administered in an amount that is effective to increase the analgesic potency of the bimodally-acting opioid agonist. As used herein, the term “effective to increase the analgesic potency of the bimodally-acting opioid agonist” is an amount that is effective to inactivate or attenuate excessive excitatory opioid receptor-mediated functions, such as anti-analgesia, hyperalgesia, hyperexcitability, physical dependence, tolerance, and other adverse effects, when it selectively blocks excitatory opioid receptor functions in nociceptive neurons. Accordingly, the agent that inhibits GM1-ganglioside in nociceptive neurons is administered at a dose which blocks the effects of the bimodally-acting opioid agonist on excitatory opioid receptors, without blocking the agonist's effects on inhibitory opioid receptors. This amount is readily determined by one skilled in the art (10, 14, 15, 52).
As described herein, the amount of GM1-ganglioside inhibitor for use in the present invention, relative to the amount of opioid agonist for use in the present invention, is not particularly crucial for achieving the augmented analgesic effects disclosed herein, because higher-than-necessary doses will not attenuate inhibitory analgesic effects. The optimum amounts of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons to be administered will depend, of course, upon the particular factors of each case, including the agonist and agent used, the carrier chosen, the route of administration, and the physical and pharmacokinetic properties of the subject being treated. As described above, examples of doses of GM1-ganglioside inhibitors include, without limitation, 10 mg/kg of Na2SO4, 0.01-1 mg/kg of CTX-B, and 0.1-1 mg/kg of oseltamivir. Oseltamivir, may be administered to a subject in a dose ranging from 0.1-1 mg/kg, once or twice a day.
In the method of the present invention, administration of a bimodally-acting opioid agonist “in combination with” an agent that inhibits GM1-ganglioside in nociceptive neurons refers to co-administration of the agonist and the agent. Co-administration may occur concurrently, sequentially, or alternately. Concurrent co-administration refers to administration of both the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons at essentially the same time. For concurrent co-administration, the courses of treatment with the bimodally-acting opioid agonist and with the agent that inhibits GM1-ganglioside in nociceptive neurons may be run simultaneously. For example, a single, combined formulation, containing both an amount of the bimodally-acting opioid agonist and an amount of the agent that inhibits GM1-ganglioside in nociceptive neurons, in physical association with one another, may be administered to the subject. The single, combined formulation may consist of an oral formulation, containing amounts of both the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons, which may be orally administered to the subject, or a liquid mixture, containing amounts of both the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons, which may be injected into the subject.
It is also within the confines of the present invention that an amount of a bimodally-acting opioid agonist and an amount of an agent that inhibits GM1-ganglioside in nociceptive neurons may be administered concurrently to a subject, in separate, individual formulations. For example, an amount of the agonist may be packaged in a vial or unit dose, and an amount of the agent may be packaged in a separate vial or unit dose, and the contents of the separate vials or unit doses then may be concurrently co-administered to the subject. Accordingly, the method of the present invention is not limited to concurrent co-administration of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons in physical association with one another.
In the method of the present invention, a bimodally-acting opioid agonist and an agent that inhibits GM1-ganglioside in nociceptive neurons also may be co-administered to a subject in separate, individual formulations that are spaced out over a brief period of time (e.g., minutes or hours), so as to obtain the maximum efficacy of the combination. Administration of the agonist and the agent may range in duration from a brief, rapid administration, to a continuous perfusion. When spaced out over a brief period of time, co-administration of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons may be sequential or alternate. For sequential co-administration, one of the compounds (i.e., either the agonist or the agent) is separately administered, followed by the other within a period of minutes or hours.
In accordance with the method of the present invention, the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons (either in separate, individual formulations, or in a single, combined formulation) may be administered to a human or animal subject by known procedures, including, without limitation, oral administration, parenteral administration (e.g., epidural, epifascial, intracapsular, intracutaneous, intradermal, intramuscular, intraorbital, intraperitoneal (particularly in the case of localized regional therapies), intrasternal, intravascular, intravenous, parenchymatous, and subcutaneous administration), nasal administration, sublingual administration, transdermal administration, and administration by osmotic pump. Preferably, the GM1-ganglioside inhibitor of the present invention is administered nasally or orally.
For oral administration, formulations of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons (whether individual or combined) may be presented in solid or liquid preparations, e.g., capsules, tablets, powders, granules, dispersions, solutions, and suspensions. Such preparations are well known in the art, as are other oral dosage forms not listed here. The formulations may have conventional additives, such as lactose, mannitol, corn starch, or potato starch. The formulations also may be presented with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch, or gelatins. Additionally, the formulations may be presented with disintegrators, such as corn starch, potato starch, or sodium carboxymethylcellulose. The formulations also may be presented with dibasic calcium phosphate anhydrous or sodium starch glycolate. Finally, the formulations may be presented with lubricants, such as talc or magnesium stearate.
For parenteral administration, formulations of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons (whether individual or combined) may be combined with a sterile aqueous solution that is preferably isotonic with the blood of the subject. Such formulations may be prepared by dissolving a solid active ingredient in water containing physiologically-compatible substances, such as sodium chloride, glycine, and the like, and having a buffered pH compatible with physiological conditions, so as to produce an aqueous solution, then rendering said solution sterile. The formulations may be presented in unit or multi-dose containers, such as sealed ampules or vials. The formulations may be delivered by any mode of injection, including, without limitation, epidural, epifascial, intracapsular, intracutaneous, intradermal, intramuscular, intraorbital, intraperitoneal (particularly in the case of localized regional therapies), intrasternal, intravascular, intravenous, parenchymatous, or subcutaneous.
For nasal administration, aerosol, nasal-mist, or nasal-spray formulations of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons (whether individual or combined) may be prepared in accordance with standard procedures known in the art for the preparation of nasal sprays. Moreover, CTX-B in the form of a spray for nasal administration may be obtained from Maxim Pharmaceuticals (San Diego, Calif.).
For transdermal administration, formulations of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons (whether individual or combined) may be combined with skin penetration enhancers, such as propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone, and the like, which increase the permeability of the skin to the agonist and the agent, and permit the agonist and the agent to penetrate through the skin and into the bloodstream. The composition of the enhancer and the agonist and/or agent also may be further combined with a polymeric substance, such as ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate, polyvinyl pyrrolidone, and the like, to provide the composition in gel form, which may be dissolved in a solvent, such as methylene chloride, evaporated to the desired viscosity, and then applied to backing material to provide a patch. The agonist and the agent may be administered transdermally, at or near the site on the subject where pain is localized. Alternatively, the agonist and the agent may be administered transdermally at a site other than the affected area, in order to achieve systemic administration.
Formulations of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons (whether individual or combined) also may be released or delivered from an osmotic mini-pump or other time-release device. The release rate from an elementary osmotic mini-pump may be modulated with a microporous, fast-response gel disposed in the release orifice. An osmotic mini-pump would be useful for controlling release, or targeting delivery, of the agonist and the agent.
In accordance with the methods of the present invention, where the bimodally-acting opioid agonist or the agent that inhibits GM1-ganglioside in nociceptive neurons is a protein, the agonist or agent protein may be administered to a subject by introducing to the subject the agonist or agent protein itself, or by introducing to the subject a nucleic acid encoding the agonist or agent, in a manner permitting expression of the agonist or agent protein. The agonist and agent of the present invention may be introduced to the subject by known techniques used for the introduction of drugs, including, for example, injection and transfusion. Where pain is localized to a particular portion of the body of the subject, it may be desirable to introduce the agonist or agent directly to that area, by injection or by some other means (e.g., by introducing the agonist or agent into the blood or another body fluid).
For non-invasive introduction of agonists and agents, micro-encapsulated preparations, such as liposomes, also may be used. Liposomal vesicles may be prepared by various methods known in the art, and liposome compositions may be prepared using any one of a variety of conventional techniques for liposome preparation known to those skilled in the art. Examples of such methods and techniques include, without limitation, chelate dialysis, extrusion (with or without freeze-thaw), French press, homogenization, microemulsification, reverse phase evaporation, simple freeze-thaw, solvent dialysis, solvent infusion, solvent vaporization, sonication, and spontaneous formation. Preparation of the liposomes may be carried out in a solution, such as an aqueous saline solution, aqueous phosphate buffer solution, or sterile water. Liposome compositions also may be prepared by various processes involving shaking or vortexing. The agonist or agent may be incorporated into the layers of a liposome, such that its intracellular domain extends outside the liposome and its extracellular domain extends into the interior of the liposome. It is expected that liposomal delivery of a bimodally-acting opioid agonist or an agent that inhibits GM1-ganglioside in nociceptive neurons will facilitate passage of the agonist or agent through the blood-brain barrier (32).
Nucleic acid encoding the bimodally-acting opioid agonist or the agent that inhibits GM1-ganglioside in nociceptive neurons, as well as any antisense oligonucleotide or other nucleotide inhibitor of GM1-ganglioside, may be introduced to the subject using conventional procedures known in the art, including, without limitation, electroporation, DEAE Dextran transfection, calcium phosphate transfection, lipofection, monocationic liposome fusion, polycationic liposome fusion, protoplast fusion, creation of an in vivo electrical field, DNA-coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, in vivo gene therapy, ex vivo gene therapy, viral vectors, and naked DNA transfer, or any combination thereof. Recombinant viral vectors suitable for gene therapy include, but are not limited to, vectors derived from the genomes of viruses such as retrovirus, HSV, adenovirus, adeno-associated virus, Semiliki Forest virus, cytomegalovirus, and vaccinia virus.
It is also within the confines of the present invention that the formulations of the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons (either in separate, individual formulations, or in a single, combined formulation) may be further associated with a pharmaceutically-acceptable carrier, thereby comprising a pharmaceutical composition. Accordingly, the present invention provides a pharmaceutical composition, comprising a bimodally-acting opioid agonist, an agent that inhibits GM1-ganglioside in nociceptive neurons, and a pharmaceutically-acceptable carrier. The pharmaceutically-acceptable carrier must be “acceptable” in the sense of being compatible with the other ingredients of the composition, and not deleterious to the recipient thereof. Examples of acceptable pharmaceutical carriers include carboxymethyl cellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methyl cellulose, powders, saline, sodium alginate, sucrose, starch, talc, and water, among others. It is also within the confines of the present invention to provide a pharmaceutical composition comprising a bimodally-acting opioid agonist and a pharmaceutically-acceptable carrier, and a pharmaceutical composition comprising an agent that inhibits GM1-ganglioside in nociceptive neurons and a pharmaceutically-acceptable carrier.
The formulations of the pharmaceutical compositions of the present invention may be conveniently presented in unit dosage. The formulations also may be prepared by methods well-known in the pharmaceutical art. For example, the active compound may be brought into association with a carrier or diluent, as a suspension or solution. Optionally, one or more accessory ingredients (e.g., buffers, flavoring agents, surface active agents, and the like) also may be added. The choice of carrier will depend upon the route of administration. The pharmaceutical composition may be useful for administering the agonist and the agent of the present invention (i.e., the bimodally-acting opioid agonist, the agent that inhibits GM1-ganglioside in nociceptive neurons, and their analogues and derivatives, either in separate, individual formulations, or in a single, combined formulation) to a subject to treat pain.
In the composition of the present invention, the bimodally-acting opioid agonist may be any of those described above. Preferably, the agonist is morphine. Additionally, in the composition of the present invention, the agent that inhibits GM1-ganglioside in nociceptive neurons may be any of those described above. Preferably, the agent is CTX-B or oseltamivir. In the composition of the present invention, the bimodally-acting opioid agonist is provided in an analgesic amount, as defined above, or a subanalgesic amount, as defined above. The agent that inhibits GM1-ganglioside in nociceptive neurons is provided in an amount effective to increase the analgesic potency of the bimodally-acting opioid agonist in a subject, as defined above. These amounts may be readily determined by the skilled artisan, or in accordance with the methods described herein.
The present invention further provides a method for treating pain in a subject in need of treatment thereof. Pain is a complex subjective sensation, reflecting real or potential tissue damage and the affective response thereto (3). Pain may be broadly classified as acute (lasting for hours or a few days) or chronic (persisting for more than one month), somatogenic or psychogenic. Somatogenic, or organic, pain may be explained in terms of physiologic mechanisms. Psychogenic pain occurs without an organic pathology sufficient to explain the degree of pain and disability, and is thought to be related mainly to psychologic issues (3).
Somatogenic pain may be nociceptive or neuropathic (3). Nociceptive pain results from ongoing activation of somatic or visceral pain-sensitive nerve fibers. When somatic nerves are affected, pain is typically felt as aching or pressure. Neuropathic pain results from dysfunction in the nervous system. It is believed to be sustained by aberrant somatosensory processes in the peripheral nervous system, the central nervous system, or both. Nociceptive pain may predominate in pain syndromes related to chronic joint or bone injury (e.g., arthritis, cancer, hemophilia, and sickle cell disease). Common classes of pain include acute postoperative pain, cancer pain, headaches, neuropathic pain (e.g., complex regional pain syndrome), and psychogenic pain syndromes (3). In the method of the present invention, the pain may be any of those described above, including acute pain and chronic pain, nociceptive pain and neuropathic pain. Preferably, the pain is nociceptive pain.
The method of the present invention comprises administering to a subject a bimodally-acting opioid agonist in combination with an agent that inhibits GM1-ganglioside in nociceptive neurons, in amounts effective to treat the pain in the subject. The subject may be any of those described above. Preferably, the subject is a human. A subject in need of treatment for pain may be a subject who is exhibiting or experiencing pain, or a subject who is about to be subjected to a pain-causing event.
In accordance with the method of the present invention, the bimodally-acting opioid agonist may be any of those described above. Preferably, the agonist is morphine. Additionally, the agent that inhibits GM1-ganglioside in nociceptive neurons may be any of those described above. Preferably, the agent is CTX-B or oseltamivir. The agonist and the agent of the present invention may be administered to a subject in need of treatment for pain by any of the methods, and in any of the formulations, described above. Preferably, the agonist and agent are administered nasally or orally. Moreover, the bimodally-acting opioid agonist and the agent that inhibits GM1-ganglioside in nociceptive neurons may be co-administered together in the same formulation, or they may be administered in separate formulations, as described above. If the agonist and the agent are co-administered in separate formulations, they may be co-administered by similar or different modes of administration, and they may be co-administered concurrently, sequentially, or alternately, as described above.
In the method of the present invention, the agonist and the agent are administered to a subject in amounts effective to treat the pain in the subject. As used herein, the phrase “effective to treat the pain” means effective to ameliorate or minimize the clinical impairment or symptoms resulting from the pain (e.g., by diminishing any uncomfortable, unpleasant, or debilitating sensations experienced by the subject). The amounts of agonist and agent effective to treat pain in a subject in need of treatment thereof will vary depending on the particular factors of each case, including the type of pain, the location of the pain, the subject's weight, the severity of the subject's condition, the agonist and agent used, and the route of administration. These amounts can be readily determined by the skilled artisan.
In one embodiment of the present invention, the amount of the bimodally-acting opioid agonist is an analgesic or subanalgesic amount, as defined above, and the amount of the agent that inhibits GM1-ganglioside in nociceptive neurons is an amount effective to increase the analgesic potency of the bimodally-acting opioid agonist, as defined above. As described above, examples of doses of GM1-ganglioside inhibitors include, without limitation, 10 mg/kg of Na2SO4, 0.01-1 mg/kg of CTX-B, and 0.1-1 mg/kg of oseltamivir.
It is within the confines of the present invention that an agent that inhibits GM1-ganglioside, as described above, can be administered alone to chronic pain patients, in order to enhance the analgesic potency and reduce the tolerance/dependence liability of endogenous opioid peptides, such as enkephalins, dynorphins, and endorphins, which are elevated in chronic pain patients (10). Accordingly, the present invention further provides a method for treating chronic pain in a subject in need of treatment thereof, comprising administering to the subject an agent that inhibits GM1-ganglioside in nociceptive neurons, in an amount effective to treat the chronic pain in the subject. The subject may be any of those described above. Preferably, the subject is a human. A subject in need of treatment for chronic pain may be a subject who is exhibiting or experiencing chronic pain. The agent that inhibits GM1-ganglioside in nociceptive neurons may be any of those described above. Preferably, the agent is CTX-B or oseltamivir.
In the method of the present invention, the agent that inhibits GM1-ganglioside in nociceptive neurons may be administered to a subject by any of the methods, and in any of the formulations, described above. The agent is administered to a subject in an amount effective to treat the chronic pain in the subject. As used herein, the phrase “effective to treat the chronic pain” means effective to ameliorate or minimize the clinical impairment or symptoms resulting from the chronic pain (e.g., by diminishing any uncomfortable, unpleasant, or debilitating sensations experienced by the subject). The amount of agent effective to treat chronic pain in a subject in need of treatment thereof will vary depending upon the particular factors of each case, including the type of pain, the location of the pain, the subject's weight, the severity of the subject's condition, the agent used, and the method of administration. This amount can be readily determined by the skilled artisan.
In one embodiment of the present invention, the amount of the agent that inhibits GM1-ganglioside in nociceptive neurons is an amount effective to increase the analgesic potency of, and reduce the tolerance to or dependence on, endogenous opioid peptides, such as enkephalins, dynorphins, and endorphins, which are elevated in chronic pain patients. Thus, the agent that inhibits GM1-ganglioside may be administered in an amount that blocks the excitatory effects (e.g., tolerance and physical dependence) of the endogenous bimodally-acting opioid agonist, without blocking the inhibitory effects (e.g., analgesic effects) of the bimodally-acting opioid agonist. As described above, examples of doses of GM1-ganglioside inhibitors include, without limitation, 10 mg/kg of Na2SO4, 0.01-1 mg/kg of CTX-B, and 0.1-1 mg/kg of oseltamivir.
Excitatory opioid receptors in nociceptive neurons may become supersensitized by chronic exposure to endogenous or exogenous bimodally-acting (excitatory/inhibitory) opioid agonists, as has been shown to occur in somatic sensory dorsal root ganglion (“DRG”) neurons. Neurons with supersensitized excitatory opioid receptor functions in nociceptive neurons, therefore, may become “physically dependent” on opioids, as occurs in somatic sensory and CNS neurons. Co-administration of 10−7 M CTX-B during chronic treatment of sensory neurons in culture with 10−6 M morphine or other bimodally-acting opioid agonists (>1 week in culture) prevented development of the opioid excitatory supersensitivity, including naloxone-precipitated APD-prolongation, as well as the tolerance to opioid inhibitory effects that generally occurs after chronic opioid exposure. CTX-B binds selectively to allosteric GM1-ganglioside binding sites on excitatory opioid receptors, thereby blocking excitatory, but not inhibitory, opioid effects (50). Co-administration of CTX-B during chronic opioid treatment prevented the development of the plastic changes in neuronal sensitivity that are considered to be cellular manifestations related to opioid dependence and tolerance in vivo (51). In view of the foregoing, agents which inhibit GM1-ganglioside in nociceptive neurons may be useful for treating opioid-mediated addictions.
Accordingly, the present invention provides a method for treating adverse excitatory effects associated with administration of a bimodally-acting opioid agonist in a subject in need of treatment thereof. The bimodally-acting opioid agonist may be any of those described above. Preferably, the agonist is morphine. Examples of adverse excitatory effects include, without limitation, anti-analgesia, hyperexcitability, hyperalgesia, physical dependence, psychological dependence, and tolerance, as well as constipation, nausea, respiratory depression, sedation, and vomiting. As used herein, a “psychological dependence” is a psychological condition which manifests as an overpowering compulsion to continue taking opioids, and a “physical dependence” is a state of physiologic adaptation to a drug, which may increase in intensity with increased dosage and duration of use of opioids, and which may manifest in a withdrawal (abstinence) syndrome when the drug is discontinued or its effect is counteracted. As further used herein, “tolerance” refers to circumstances where the dosage of a bimodally-acting opioid agonist must be increased in order to obtain the initial effect.
The method of the present invention comprises administering to a subject an agent that inhibits GM1-ganglioside in nociceptive neurons, in an amount effective to treat the adverse excitatory effects in the subject. The subject may be any of those described above. Preferably, the subject is a human. The agent that inhibits GM1-ganglioside in nociceptive neurons may be any of those described above. Preferably, the agent is CTX-B or oseltamivir.
As used herein, the term “effective to treat the adverse excitatory effects” means effective to ameliorate or minimize the clinical impairment or symptoms resulting from the adverse excitatory effects (e.g., by diminishing any tolerance to, or any psychological or physical dependence on, the opioid agonist). By attenuating tolerance to, and psychologic or physical dependence on, the opioid agonist, the agent that inhibits GM1-ganglioside in nociceptive neurons may produce added secondary benefits, including an increase in the analgesic potency of the bimodally-acting opioid agonist, and a decrease in side-effects associated with chronic opioid use or overdose and the withdrawal therefrom (e.g., aching muscles, anorexia, anxiety, craving for the opioid, hot and cold flashes, increased respiratory rate, itching, lacrimation, muscle twitching, mydriasis, perspiration, piloerection, rhinorrhea, tremors, etc.).
The agent of the present invention may be administered to a subject by any of the methods, and in any of the formulations, described above. The amount of agent effective to treat tolerance to or an addiction to a bimodally-acting opioid agonist in a subject in need of treatment thereof will vary depending upon the particular factors of each case, including the type of tolerance or addiction, the extent of the tolerance or addiction, the subject's weight, the severity of the subject's condition, the agent used, and the method of administration. This amount can be readily determined by the skilled artisan. In one embodiment of the present invention, the amount of the agent that inhibits GM1-ganglioside in nociceptive neurons is an amount effective to increase the analgesic potency of the bimodally-acting opioid agonist, as defined above. Thus, the agent that inhibits GM1-ganglioside may be administered in an amount that blocks the excitatory effects (e.g., tolerance and physical dependence) of the bimodally-acting opioid agonist, without blocking the inhibitory effects (e.g., analgesic effects) of the bimodally-acting opioid agonist. This amount is readily determined by one skilled in the art. As described above, examples of doses of GM1-ganglioside inhibitors include, without limitation, 10 mg/kg of Na2SO4, 0.01-1 mg/kg of CTX-B, and 0.1-1 mg/kg of oseltamivir.
The present invention is described in the following Experimental Details section, which is set forth to aid in the understanding of the invention, and should not be construed to limit in any way the scope of the invention as defined in the claims which follow thereafter.
Electrophysiologic studies of nociceptive types of mouse dorsal-root ganglion (DRG) neurons in culture have shown that specific μ, δ, and κ opioid agonists evoke naloxone-reversible prolongation of the action potential duration (APD), when applied to many of these neurons at low nanomolar (nM) concentrations (9, 48). In contrast, as shown in previous studies, higher micromolar (μM) levels of opioids shorten the APD (7, 57). This bimodal modulation of the APD in DRG neurons, by exposure to either low or high concentrations of opioid agonists, appears to be due to activation of excitatory or inhibitory opioid receptor functions.
Treatment with pertussis toxin (PTX), which uncouples inhibitory receptors linked to the regulatory G-proteins, Gi and Go (29, 36), blocks opioid-induced shortening of the APD in DRG neurons (48) and opioid depression of DRG-evoked postsynaptic dorsal-horn network responses in DRG-cord explants (16). Contrastingly, opioid-induced APD prolongation in DRG neurons is blocked by treatment with the A subunit of cholera toxin (CTX-A) (49), which interferes with ligand-activation of Gs-linked excitatory receptors.
CTX-A selectively catalyzes the ADP-ribosylation of Gs (28, 40), resulting in inhibition of an associated GTPase (6), increased adenylate cyclase activity, and decreased efficacy of ligand activation of Gs-coupled receptors (5, 6, 38, 41, 55). Brief treatment of DRG neurons with very low concentrations of purified CTX-A, or with whole toxin (1 pg/ml to 1 ng/ml), selectively blocks opioid-induced prolongation of the APD, thereby providing strong evidence for mediation of this excitatory modulatory effect by opioid receptors linked to a Gs/protein kinase A/cAMP second-messenger system (9, 17, 49).
Pretreatment of DRG neurons with CTX-B (1-10 ng/ml) also selectively blocks opioid-induced APD prolongation, but not opioid-induced APD shortening (49). In contrast to CTX-A blockade of opioid excitatory effects by ADP-ribosylation of Gs, CTX-B blockade appears to involve interference with GM1-ganglioside regulation of opioid excitatory receptor functions. This conclusion is based on the specificity of CTX-B in binding with selective high affinity (KD=10−10M) to GM1-ganglioside, which is abundantly distributed on the external surface of neuronal cell membranes (23, 24, 25, 37, 59). Treatment of DRG neurons with anti-GM1 antibodies also selectively blocks opioid-induced APD prolongation, as occurs with CTX-B (49).
Subsequent studies have shown that, following brief treatment of DRG neurons with low (10 nM) concentrations of GM1 (but not GM2, GM3, or other gangliosides or glycolipids), the threshold concentration of the opioid peptide dynorphin, which is required to prolong the APD in many DRG neurons, is markedly decreased from nM levels to fM-pM levels (49, 53). These electrophysiologic studies suggest that the increased sensitivity of GM1-treated DRG neurons to the excitatory effects of opioid agonists is due to GM1 binding to an allosteric regulatory site on opioid receptors (50), which appears to enhance the efficacy of excitatory, Gs-coupled opioid receptor functions (12).
The increased sensitivity of GM1-treated DRG neurons to the excitatory effects of opioid agonists is consonant with recent evidence that injection (i.p.) of low doses of GM1 (0.1 mg/kg) in mice rapidly attenuates morphine's analgesic effects (13). The present study provides more direct evidence that endogenous GM1-ganglioside plays a physiologic role in regulating excitatory opioid receptor functions in vivo, by demonstrating that remarkably low doses of CTX-B (10 ng/kg; s.c.) selectively block low-dose μ- and κ-opioid-induced hyperalgesic effects, thereby unmasking potent opioid analgesia. These results are comparable to the effects of cotreatment of mice with morphine and ultralow doses of NTX (10, 15, 52), which block low-dose, opioid-induced hyperalgesic effects, thereby unmasking potent opioid analgesia. Low-dose NTX selectively blocks excitatory opioid receptors at their recognition site, whereas CTX-B binds to, and interferes with, a putative allosteric GM1 regulatory site on excitatory opioid receptors (11, 12, 49). Furthermore, chronic cotreatment of mice with morphine and CTX-B also attenuates development of opioid tolerance and physical dependence, as previously shown to occur during cotreatment with low-dose NTX (10, 52).
A. Antinociception and Hyperalgesia Assays in Mice
Swiss-Webster (SW) male and female mice (20-25 g; Charles River, N.Y.) were housed separately in groups of five, maintained on a 12-hour light/dark cycle, and provided water and food ad libitum for 1-3 days prior to antinociception testing. Antinociceptive and hyperalgesic effects of opioids were measured on these mice using a hot-water-immersion tail-flick assay similar to those previously described (10, 13, 33, 52). Each mouse was permitted to enter into a tapered plastic cylinder with air holes. The size of the cylinder was slightly larger than the size of the animal's body, such that the tail could hang out freely from the cylinder. The cylinder provided a secluded environment into which the animal voluntarily entered with no application of force.
During the tail-flick assay, only the cylinder was handled, and there was not direct contact with the animal. One third of the tail, measured from the tip, was immersed into a water bath that was maintained at 52° C. or 55° C. (±0.1°) with an electronic thermoregulator (Yellow Springs). The latency to a rapid tail-flick was recorded. Mice with control latencies >8 sec were excluded from these tests, and a 10-second cutoff was used to minimize tissue damage. Six sequential control tests were made, each with a 10-minute interval. The latencies of the last 4 tests were averaged to provide a pre-drug value. Time-effect curves were plotted using tail-flick latencies as the ordinate (13).
B. Animal Test Groups
Comparative tests were generally carried out on the same day, with two or more groups of 8 mice receiving a specific cotreatment, plus an appropriate control group of 8 mice treated with morphine (or other opioid test agonist) alone. Each animal test group was used for only one assay, except for the chronic drug treatment tests.
C. Statistical Analyses
Differences between treatment groups were examined for statistical significance by means of ANOVA with Neuman-Keuls tests, or by means of a Students' t test (56).
D. Materials
The following drugs were used: NTX, morphine, naloxone (NLX), and U-50,488H (Sigma); CTX-B (“choleragenoid”) and recombinant CTX-B (List); and oseltamivir (“Tamiflu”; Roche Laboratories, Nutley, N.J.). Stock solutions of CTX-B (commercially purified from whole CTX) were heated to 56° C. for 20 min, to eliminate possible traces of CTX-A in the commercial product. This protocol was based upon the inventors' previous study that showed that the potent blocking effects of both CTX-A (tested up to 1 μg/ml) and whole CTX (tested up to 1 ng/ml) on opioid excitatory modulation of the APD were completely eliminated after this heat treatment (50). In contrast to the thermolabile, enzymatic properties of the A subunit, preparations of the B subunit of CTX showed relatively little loss in potency after heating to 56° C. These results demonstrate that pretreatment of DRG neurons with CTX-B can block opioid-induced APD prolongation, even under conditions which preclude effects mediated by the A subunit. Control tests were also carried out on some groups of mice that had been injected with recombinant CTX-B (rCTX-B), which had been produced and purified from a recombinant strain of Vibrio cholerae lacking the CTX-A gene (45).
A. Cotreatment of Mice with CTX-B Blocks Acute, Low-Dose, Morphine-Induced Thermal Hyperalgesia, Thereby Unmasking Potent Opioid Analgesia
Hot-water-immersion (52° C.) nociceptive assays in normal, naïve SW mice resulted in control tail-flick latencies of about 4 sec (15). Administration to these mice of very low doses of morphine (ca. 1 μg/kg; s.c.) resulted in rapid onset of decreases in tail-flick latencies (ca. 1-2 sec) which lasted for 4-5 h after drug injection (
In order to confirm that the inventors' heat treatment of regular CTX-B did, in fact, eliminate trace amounts of CTX-A, several groups of mice were tested with recombinant CTX-B. Cotreatment with the same or even lower doses of rCTX-B (10 ng/kg) also blocked low-dose, morphine-induced hyperalgesia, thereby unmasking potent opioid analgesia (
B. Cotreatment with CTX-B Blocks Acute, Low-Dose, κ-Opioid-Induced Hyperalgesia, Unmasking Potent Analgesia
Acute hyperalgesia elicited by the κ-opioid agonist, U-50,488H (10 ng/kg) (
C. Acute Cotreatment of Mice with CTX-B Markedly Prolongs the Analgesic Effects of Higher Doses of Morphine
A series of antinociceptive tail-flick assays of the effects of CTX-B cotreatment on morphine analgesia was also carried out using a slightly higher water-immersion temperature (55° C.), as utilized in the inventors' previous studies with low-dose NTX cotreatment (52). In assays at 55° C., control tail-flick latencies were about 2 sec, making possible hyperalgesic effects more difficult to quantify (cf.
D. Chronic Cotreatment of Mice with Morphine Plus CTX-B Prevents the Development of Opioid Tolerance
In another group of mice, acute cotreatment with CTX-B also markedly enhanced the magnitude, as well as the duration, of morphine's antinociceptive effects (
E. Chronic Cotreatment of Mice with Morphine Plus CTX-B Prevents Development of NLX-Precipitated Withdrawal Hyperalgesia
Injection of naïve mice with low doses of NLX or NTX did not alter the baseline tail-flick latency in the inventors' antinociceptive assays (10, 52). In contrast, after chronic morphine treatment (e.g., 10 mg/kg for 5-6 days), withdrawal of morphine and injection of 10 μg/kg NLX evoked a prominent hyperalgesic response that lasted for more than 5 h. This response was comparable in magnitude and duration to that elicited by low-dose morphine in naïve mice (
F. Oral Cotreatment of Male and Female Mice with CTX-B Blocks Hyperalgesic Effects of Morphine Injections, Unmasking Potent Analgesia
CTX-B was added to the drinking-water bottles of groups of male, as well as female, mice for 1 day prior to antinociceptive assays using low-dose morphine (0.1 μg/kg; s.c.). Both male and female mice showed prominent, long-lasting antinociception after pretreatment with CTX-B, in sharp contrast to the marked hyperalgesia elicited by this low dose of morphine in control groups of mice (
G. Cotreatment of Mice with Oseltamivir and Other Neuraminidase Inhibitors Blocks Excitatory Opioid Receptor Functions by Interference with GM1 Regulation of these Receptors
Administration of exogenous neuraminidase has been shown markedly to increase the concentrations of the monosialoganglioside GM1 in membranes of DRG and other neurons, by enzymatic removal of neuraminic (sialic) acid from polysialylated ligands of the gangliotetraose series in these neurons (11, 53, 59, 60, 64, 65, 69). This specific effect of neuraminidase on the enzymatic conversion of polysialylated gangliosides to GM1 in neurons is quite distinct from the roles of neuraminidase in promoting influenza virus release from infected cells and in facilitating virus spread within the respiratory tract. The antiviral effects of neuraminidase inhibitors may involve removal of sialic acid from cell surface glycoproteins, in contrast to removal of sialic acid from neuronal glycolipids.
Further studies, involving inhibitors of neuraminidase, have provided additional evidence that endogenous GM1-ganglioside plays a physiologic role in regulating excitatory opioid receptor-mediated functions in vivo. In particular, it was demonstrated that the neuraminidase inhibitor, oseltamivir (Tamiflu), selectively blocks morphine's hyperalgesic effects, thereby unmasking potent opioid analgesia (
The present study in mice suggests that clinical administration of oseltamivir at doses that result in neuraminidase inhibition of influenza virus (66) concomitantly may be effective in decreasing GM1-ganglioside levels in nociceptive neurons. The latter result would attenuate the efficacy of GM1-regulated, Gs-coupled, excitatory opioid receptor-mediated hyperalgesic functions, thereby unmasking Gi/Go-coupled inhibitory opioid receptor-mediated analgesia and reducing development of tolerance and physical dependence. It is expected that cotreatment with oseltamivir plus morphine would result in similar effects in both sexes, as has been shown to occur in recent tests with CTX-B plus morphine in male and female mice.
Recently, it has been demonstrated that inorganic sulfates (e.g., Na2SO4) have potent inhibitory effects on mammalian neuraminidase activity in cultures of human macrophagic cells (70). In view of the remarkable effectiveness of oseltamivir in enhancing morphine analgesia and attenuating tolerance/dependence, as described above, the inventors carried out similar antinociception assays on mice cotreated with 3 μg/kg morphine plus 10 mg/kg Na2SO4. The results were surprisingly similar to those obtained with the much more complex neuraminidase inhibitor, oseltamivir. Chronic cotreatment of mice with 10 mg/kg of Na2SO4 plus 3 mg/kg of morphine enhanced analgesia, prevented development of tolerance during daily injections for 5 days, and prevented NLX-precipitated withdrawal hyperalgesia when tested on the sixth day. This unexpectedly simple procedure for enhancing morphine's analgesic potency and attenuating tolerance/dependence is counterintuitive, because several studies showing enhancement of morphine analgesia by cotreatment with MgSO4 have been attributed to the antagonist effect of magnesium on excitatory NMDA-receptor functions, without recognition of the possible causal influence of sulfate (4, 21, 22, 42).
The results of the present study provide strong evidence that GM1-binding to excitatory, Gs-coupled opioid receptors plays a physiologic role in regulating these receptors on neurons in nociceptive networks in vivo. The inventors previously showed that injection of low doses of exogenous GM1 (0.1-1 mg/kg; i.p.) in mice rapidly attenuates morphine's analgesic effects (“acute tolerance”) (13), presumably by enhancing the efficacy of excitatory opioid receptor functions of nociceptive neurons. This interpretation is supported by the present evidence that injection of remarkably low doses of CTX-B (s.c.) rapidly blocks acute opioid-induced hyperalgesic effects, thereby unmasking potent opioid analgesia.
A. Consonance of CTX-B Blockade of Opioid-Induced Hyperalgesia in Mice and CTX-B Blockade of Excitatory Opioid Receptor-Mediated Functions in DRG Neurons in Culture
A possible role for GM1-ganglioside in regulating excitatory opioid receptor-mediated functions was initially proposed after it was observed that acute application of CTX-B to DRG neurons blocks excitatory, but not inhibitory, opioid receptor functions (50). Because CTX-B binds selectively to GM1-ganglioside on neuronal cell membranes, this result suggested that CTX-B might thereby interfere with a putative allosteric GM1 regulatory site on Gs-coupled excitatory opioid receptors (50).
Studies on DRG neurons also showed that CTX-blockade of opioid-induced excitatory, APD-prolonging effects in DRG neurons does not appear to be due to direct interference with ion-channel functions. Firstly, exposure to CTX-B alone did not result in significant alterations in the APD of DRG neurons. Secondly, exposure to forskolin resulted in characteristic prolongation of the APD in CTX-B treated neurons, demonstrating that CTX-B did not interfere with the responsiveness of cAMP-dependent ion channels, which mediate the excitatory effects of forskolin (30, 48, 58) and opioids (8, 9, 12, 48). Furthermore, in recent studies of non-opioid, GM1-deficient Chinese hamster ovary (CHO) cells transfected with cloned opioid receptors, acute application of GM1-ganglioside resulted in rapid (ca. 30 min) conversion of these receptors from an inhibitory, Gi-coupled mode to an excitatory, Gs-coupled mode (11, 12, 61).
CTX-B blockade of acute, low-dose, opioid-induced hyperalgesia and unmasking of potent opioid analgesia in mice is remarkably consonant with the inventors' previous studies of CTX-B effects on DRG neurons in culture. Cotreatment of DRG neurons with 1-10 ng/ml CTX-B blocked low-dose (1-10 nM) μ-, δ-, and κ-opioid-induced excitatory, APD-prolonging (“hyperalgesic”) effects in ˜15 min, unmasking potent opioid inhibitory APD-shortening (“analgesic”) effects, which required 100- to 1,000-fold higher opioid concentrations when applied alone (50).
B. Attenuation of Opioid Tolerance and Physical Dependence by Chronic Cotreatment with CTX-B
Attenuation of tolerance in chronic opioid-exposed mice resulted from cotreatment with CTX-B. This effect is consonant with the inventors' previous study on DRG neurons in culture, which showed that chronic cotreatment with nM concentrations of CTX-B attenuated development of tolerance to the inhibitory, APD-shortening effects of μM concentrations of the stable δ/μ opioid peptide, D-ala2-D-leu5-enkephalin (DADLE) (51).
Attenuation of the development of tolerance in chronic opioid-treated DRG neurons in culture, and in mice in vivo, by cotreatment with CTX-B or low-dose NTX (10, 52) can be attributed to the selective blockade of excitatory, Gs-coupled opioid receptor functions (which would otherwise be upregulated and supersensitized during chronic exposure to a bimodally-acting opioid agonist), thereby unmasking inhibitory opioid receptor functions (10, 12, 51, 74). It should be noted, however, that, in both the present in vivo study (
Additionally, prevention of NLX-precipitated withdrawal hyperalgesia in chronic morphine-treated mice, by cotreatment with CTX-B, is remarkably consonant with the inventors' study of chronic opioid-treated DRG neurons in culture, in which NLX-precipitated, excitatory, APD-prolonging effects in opioid-supersensitized neurons (10, 74) were prevented by chronic cotreatment with CTX-B (51). The present demonstration of NLX-precipitated withdrawal hyperalgesia in chronic morphine-treated mice presents a valuable new assay that may provide a measure of spinally-mediated physical dependence, thereby extending previous studies of NLX-precipitated withdrawal-jumping which may involve brainstem, as well as spinal, mechanisms (12). Interestingly, the low dose of NLX (10 μg/kg) used to evoke hyperalgesia in chronic morphine-treated mice was comparable to doses used clinically to elicit severe autonomic withdrawal symptoms in opiate-dependent humans (73).
C. CTX-B Cotreatment Blocks κ- as well as μ-Opioid-Induced Hyperalgesia in Mice
The present study demonstrates that the acute hyperalgesic effects of low doses of the specific κ-opioid agonist, U-50,488H, as well as the μ agonist, morphine, are blocked by CTX-B, such that potent opioid analgesia is unmasked. Hyperalgesia induced in mice by 10 ng/kg U-50,488H is an effect that is consonant with a previous report (1) that indicated that a low dose of the κ-opioid peptide, dynorphin (0.5 μg/kg; s.c.), resulted in thermal hyperalgesia in mice, as measured by a significant decrease in tail-flick latency (tested at 90 min post-injection). In contrast, a 100-fold higher dose (50 μg/kg) elicited analgesia (1). The present study extends the previous report (1) by showing that low-dose, κ-opioid-induced hyperalgesia can be selectively blocked by ultralow doses of the specific κ-opioid antagonist, nor-binaltorphimine, and by NTX and CTX-B. The inventors' results also are in agreement with evidence that the hyperalgesia observed within 1 h after i.v. injection of a low, 5-mg dose of the κ-opioid agonist, nalbuphine, in male dental-pain patients is blocked by cotreatment with 0.5 mg naloxone, unmasking prominent analgesia (26).
D. Efficacy and Reversibility of CTX-B in Blocking Opioid-Induced Hyperalgesia
It is surprising that subcutaneous injection of doses of CTX-B as low as 10-100 ng can reach sufficient numbers of putative allosteric GM1-binding sites on excitatory opioid receptors on nociceptive neurons, so as to block low-dose, opioid-induced hyperalgesia in <30 min after administration. Perhaps some of the CTX-B molecules can enter the spinal cord via dorsal roots, and thereby contact opioid receptors on presynaptic terminals of nociceptive DRG neurons, as the inventors have suggested may account for the similarly surprising enhancement of excitatory opioid effects by intraperitoneal injection of low doses of exogenous GM1 in mice (13).
CTX-B association with GM1-containing membranes appears to result in a localized disturbance of membrane phospholipid packing (35). Initial disruption of membrane packing by CTX-B has been proposed to result from the rigid placement of five GM1 molecules within the membrane, following association with CTX-B (43). This arrangement could create a geometry in which the area available for occupation by phospholipids is reduced by 25% or more between the fixed positions of the five GM1 molecules bound by the CTX-B pentamer (43, 31). Such physicochemical interactions may underlie the efficacy of CTX-B in binding to GM1 sites on excitatory opioid receptors, thereby blocking opioid-induced hyperalgesia.
Interestingly, CTX-B is currently utilized clinically in oral and nasal mucosal vaccines (32, 44), and its immunopotentiating capacity as a carrier molecule is considered to be related to its ability to bind GM1 on the cell membranes of immunocytes (20, 34, 54). In view of the clinical studies with oral CTX-B, the inventors carried out preliminary tests in mice to determine the effects of orally-administered CTX-B on opioid analgesia. Injection of low-dose morphine (s.c.) in mice pretreated with oral CTX-B (via their drinking water) resulted in analgesia, rather than hyperalgesia (
The inventors' antinociceptive assays in mice cotreated with morphine plus CTX-B demonstrate that CTX-B blockade of opioid hyperalgesia and enhancement of analgesia is effective for >6 h after drug injection (
E. Cotreatment of Mice with Whole CTX Blocks Excitatory Opioid Receptor Functions by CTX-A-Mediated Interference with Gs Coupling, whereas CTX-B Interferes with GM1 Regulation of these Receptors
Intracerebroventricular (i.c.v.) injection of whole CTX in mice has been reported to markedly enhance the analgesic potency of morphine, presumably by “impairing the function of Gs transducer proteins” (46). Furthermore, it has been shown that intrathecal injection of whole CTX in mice inhibits the “antianalgesic action” of dynorphin, which appeared to be “mediated by activation of [excitatory] Gs-coupled opioid receptors” (2). These interpretations are supported by the following evidence: (1) i.c.v. injection of mice with antibodies directed against Gsα also enhance morphine antinociception (47); and (2) downregulation of the Gsα protein by intrathecal injection of antisense oligonucleotides in mice results in blockade of low-dose, morphine-induced hyperalgesia (19) and tolerance during chronic morphine treatment (18).
The studies with whole CTX in mice are consistent with selective blockade of excitatory opioid receptor functions by low-dose, CTX-A-mediated interference with Gs coupling of these receptors, as previously demonstrated with both whole-CTX-treated and CTX-A-treated DRG neurons in culture (49). In contrast, the present study shows that cotreatment with the non-toxic CTX-B subunit can result in remarkably similar blockade of excitatory opioid receptor functions by interference with GM1 regulation of these Gs-coupled receptors.
All publications mentioned hereinbove are hereby incorporated in their entireties. While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art, from a reading of the disclosure, that various changes in form and detail can be made without departing from the true scope of the invention in the appended claims.
This application claims the benefit of U.S. Provisional Application No. 60/278,529, filed Mar. 23, 2001.
| Number | Date | Country | |
|---|---|---|---|
| 60278529 | Mar 2001 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10459418 | Jun 2003 | US |
| Child | 12586518 | US | |
| Parent | 10101806 | Mar 2002 | US |
| Child | 10459418 | US |
